AI-powered cardiovascular imaging software for plaque characterization and treatment planning
Elucid builds AI-driven medical imaging software to quantify atherosclerotic plaque and guide cardiovascular treatment decisions. The tech stack reveals a sophisticated cloud-native architecture: C++, CUDA, and Kubernetes on AWS, paired with containerized CI/CD (CircleCI, GitLab) and security instrumentation (GuardDuty, Security Hub, CloudTrail). The hiring mix is weighted toward senior and principal engineers alongside security roles, reflecting the company's current focus on FDA-regulated infrastructure hardening, scalable validation frameworks, and secure SDLC integration—not feature velocity.
Elucid is a Boston-based medical technology company founded in 2013, focused on non-invasive cardiovascular imaging analysis. The company provides physicians with software-based insights into plaque composition and vessel physiology through CT angiography analysis, including proprietary FFRct calculations. Their platform is designed for deployment as a SaaS offering in clinical settings, supporting integration into existing cardiovascular workflows. The 51–200 person organization is currently hiring across engineering, product, sales, and security in the United States.
Elucid uses C++, CUDA, Python, and Rust for core algorithms, deployed on AWS infrastructure via Kubernetes and Fargate. The platform employs Docker containerization, GitLab/CircleCI for CI/CD, and Datadog/New Relic for observability.
Elucid is headquartered in Boston, Massachusetts and currently hiring in the United States.
Other companies in the same industry, closest in size
Elucid's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.